|
|
IL-36受体拮抗剂治疗泛发性脓疱型银屑病的机制及研究进展
|
Abstract:
泛发性脓疱型银屑病(Generalized Pustular Psoriasis, GPP)是一种感染、遗传及免疫等多因素介导的慢性炎症性皮肤病，其治疗困难，病情可迁延不愈，并合并多器官功能损害，对患者生理健康造成重大影响。近年来国内外发现IL36RN突变是GPP的主要致病基因，IL-36信号通路成为了其发病机制重要的一环，在此基础上提出并研究了IL-36受体拮抗剂对GPP的靶向药物治疗并取得了突破性进展Spesolimab (司柏索利)的产生。作为一种新的IL-36R单克隆抗体，通过阻断IL-36R信号通路达到治疗GPP的作用，进一步了解IL-36受体拮抗剂治疗机制及目前研究进展，对中国泛发性脓疱型银屑病患者有着重要临床意义。
Generalized Pustular Psoriasis is a chronic inflammatory skin disease, mediated by many factors such as infection, heredity and immunity. It is difficult to be treated, has a significant impact on the patient’s physical health. In recent years, the mutation of IL36RN has been found to be the major pathogenic gene of GPP, and the IL-36 signal pathway has become an important link in the patho-genesis of GPP. On this basis, we proposed and studied the target drug therapy for GPP by IL-36 re-ceptor antagonist and made a breakthrough progress, Spesolimab. As a new biologics of IL-36R, it can interdict the signal pathway of IL-36R to treat GPP, as to further understand the mechanism of IL-36R antagonist therapy and the current research progress, has important clinical significance for Chinese patients with generalized pustular psoriasis.
| [1] | Masaaki, Y., Yasutomo, I., et al. (2013) Serum Cytokines Correlated with the Disease Severity of Generalized Pustular Psoriasis. Disease Markers, 34, 153-161. https://doi.org/10.1155/2013/702763 |
| [2] | 丁晓岚, 王婷琳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010, 24(7): 598？601. |
| [3] | Furue, K., Yamamura, K., et al. (2018) Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis. Acta Dermato-Venereologica, 13, 16-18. https://doi.org/10.2340/00015555-2808 |
| [4] | Johnston, A., Xing, X., et al. (2016) IL-1 and IL-36 Are Dominant Cytokines in Generalized Pustular Psoriasis. The Journal of Allergy and Clinical Immunology, 140, 109-120. https://doi.org/10.1016/j.jaci.2016.08.056 |
| [5] | Ly, K., Beck, K.M., et al. (2019) Diagnosis and Screening of Pa-tients with Generalized Pustular Psoriasis. Psoriasis: Targets and Therapy, 9, 37-42. https://doi.org/10.2147/PTT.S181808 |
| [6] | Li, L., et al. (2019) Variants of CARD14 Are Predisposing Factors for Generalized Pustular Psoriasis (GPP) with Psoriasis Vulgaris but Not for GPP Alone in a Chinese Population. The Brit-ish Journal of Dermatology, 180, 425-426.
https://doi.org/10.1111/bjd.17392 |
| [7] | Sophie, T., Alshimaa, M., et al. (2018) Clinical and Genetic Differences between Pustular Psoriasis Subtypes. Journal of Allergy and Clinical Immunology, 143, 1021-1026. |
| [8] | M？ssner, R., et al. (2018) The Genetic Basis for Most Patients with Pustular Skin Disease Remains Elusive. The British Journal of Dermatology, 178, 101-111. https://doi.org/10.1111/bjd.15867 |
| [9] | 李璐璐. 中国汉族人群泛发性脓疱型银屑病与IL36RN、CARD14、AP1S3基因相关性研究[D]: [硕士学位论文]. 济南: 济南大学, 2018. |
| [10] | Onoufriadis, A., Simpson, M.A., et al. (2011) Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. The American Journal of Human Genetics, 89, 432-437. https://doi.org/10.1016/j.ajhg.2011.07.022 |
| [11] | Sugiura, K., et al. (2013) The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist. Journal of Investi-gative Dermatology, 133, 2514-2521.
https://doi.org/10.1038/jid.2013.230 |
| [12] | Slaheddine, M., Philippe, G., et al. (2011) Interleukin-36-Receptor An-tagonist Deficiency and Generalized Pustular Psoriasis. The New England Journal of Medicine, 365, 620-628. https://doi.org/10.1056/NEJMoa1013068 |
| [13] | Iznardo, H. and Puig, L. (2021) Exploring the Role of IL-36 Cyto-kines as a New Target in Psoriatic Disease. International Journal of Molecular Sciences, 22, 43-44. https://doi.org/10.3390/ijms22094344 |
| [14] | Li, Z.T., et al. (2018) Genetic Polymorphism of IL36RN in Han Pa-tients with Generalized Pustular Psoriasis Alone in Sichuan Region. Journal of Sichuan University Medical Science Edi-tion, 49, 582-586. |
| [15] | Zhou, L. and Todorovic, V. (2020) Interleukin-36: Structure, Signaling and Function. Advances in Experimental Medicine and Biology, 21, 191-210. |
| [16] | Taube, M., et al. (2016) IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases. The Journal of Investigative Dermatology, 136, 1811-1819.
https://doi.org/10.1016/j.jid.2016.04.038 |
| [17] | Gemma, L., et al. (2020) Keratinocyte Interleukin-36 Receptor Ex-pression Orchestrates Psoriasiform Inflammation in Mice. Life Science Alliance, 3, e201900586. https://doi.org/10.26508/lsa.201900586 |
| [18] | Bissonnette, R., Suárez-Fari？as, M., et al. (2016) Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases That Appear to Be Distinct from Psoriasis Vulgaris. PLoS ONE, 11, e0158190. https://doi.org/10.1371/journal.pone.0158190 |
| [19] | Silke, F., et al. (2013) The Novel Cytokine Interleukin-36α Is Expressed in Psoriatic and Rheumatoid Arthritis Synovium. Annals of the Rheumatic Diseases, 72, 1569-1574. https://doi.org/10.1136/annrheumdis-2012-202264 |
| [20] | Chen, H., Wang, Y., et al. (2012) Alterations of Plasma Inflammatory Biomarkers in the Healthy and Chronic Obstructive Pulmonary Disease Patients with or without Acute Exacerbation. Journal of Proteomics, 75, 2835-2843.
https://doi.org/10.1016/j.jprot.2012.01.027 |
| [21] | Hovhannisyan, Z., Liu, N., et al. (2020) Enhanced IL-36R Signal-ing Promotes Barrier Impairment and Inflammation in Skin and Intestine. Science Immunology, 5, eaax1686. https://doi.org/10.1126/sciimmunol.aax1686 |
| [22] | Catapano, M., Ciccarelli, F., et al. (2017) 329 An Investigation of the Molecular Pathogenesis of Generalized Pustular Psoriasis and Its Overlap with Psoriasis Vulgaris. Journal of Inves-tigative Dermatology, 137, 524.
https://doi.org/10.1016/j.jid.2017.07.524 |
| [23] | Hal, B., Huyen, D., et al. (2007) Opposing Activities of Two Novel Members of the IL-1 Ligand Family Regulate Skin Inflammation. The Journal of Experimental Medicine, 204, 2603-2614. https://doi.org/10.1084/jem.20070157 |
| [24] | 赵丽诗, 龙福泉. 生物制剂治疗泛发性脓疱型银屑病的研究进展[J]. 中国皮肤性病学杂志, 2020, 34(3): 333-337. |
| [25] | 《脓疱型银屑病诊疗中国专家共识》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识(2022版) [J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
| [26] | Bachelez, H., Choon, S.E., et al. (2019) Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. New England Journal of Medicine, 380, 981-983. https://doi.org/10.1056/NEJMc1811317 |
| [27] | Bachelez, H., et al. (2021) Trial of Spesolimab for Generalized Pustular Psoriasis. The New England Journal of Medicine, 385, 2431-2440. https://doi.org/10.1056/NEJMoa2111563 |
| [28] | Baum, P., et al. (2021) Pustular Psoriasis: Molecular Pathways and Effects of Spesolimab in Generalized Pustular Psoriasis. Journal of Allergy and Clinical Immunology, 149, 1402-1412. https://doi.org/10.1016/j.jaci.2021.09.035 |
| [29] | Andreas, P., Christian, B.-H., et al. (2021) 26589 Spesolimab, an IL-36R Inhibitor, May Reduce Symptoms of Pain in Patients with Palmoplantar Pustulosis—Results from a Small Pilot Study. Journal of the American Academy of Dermatology, 85, AB108. https://doi.org/10.1016/j.jaad.2021.06.452 |
| [30] | Mrowietz, U., et al. (2021) Spesolimab, an Anti-Interleukin-36 Re-ceptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Random-ized, Placebo-Controlled Pilot Study. Dermatology and Therapy, 11, 571-585. https://doi.org/10.1007/s13555-021-00504-0 |
